Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | Unknown | PO / MO |
The patient missed the last dose and it's been a week overdue; Case reference number US-BN-2025-001289 is a spontaneous case initially received from nurse via Communication (reference number: USBAV25-1778) on 21-Jul-2025 and concerns an 18-year-old male patient. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient took first dose of Vivotif (batch number: unknown) orally, *at a dose of one capsule, reported as 100 percent*, for pre travel to [withheld] in August. On an unspecified date, unknown amount of time after first dose, the patient took second dose of Vivotif (batch number: unknown) orally, *at a dose of one capsule, reported as 100 percent*. On an unspecified date, unknown amount of time after second dose, the patient took third dose of Vivotif (batch number: unknown) orally, at unknown dose. On an unspecified date, the patient missed the fourth dose of Vivotif with the fourth dose scheduled for Friday and it's been a week (explicitly coded as 'missed dose'). At the time of the *follow-up report, the patient did not* experience any adverse event due to Vivotif. All follow-up information is blended into the case narrative above, with the latest information presented between asterisks (*). Follow up information received from a nurse on 13-Oct-2025: New information included Vivotif dosing details and confirmation that no adverse event experienced by the patient due to Vivotif.; Reporter's Comments: An 18-year-old male patient missed the fourth dose of Vivotif for pre travel to [withheld], which is considered as missed dose. The patient did not experience any adverse event due to Vivotif. Product dose omission issue is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product dose omission issue is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: An 18-year-old male patient missed the fourth dose of Vivotif for pre travel to [withheld], which is considered as missed dose. The patient did not experience any adverse event due to Vivotif. Product dose omission issue is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product dose omission issue is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.